Abstract:Lennox-Gastaut syndrome (LGS), a childhood-onset severe developmental and epileptic encephalopathy (DEE), is an entity that encompasses a heterogenous group of aetiologies, with no single genetic cause. It is characterised by multiple seizure types, an abnormal EEG with generalised slow spike and wave discharges and cognitive impairment, associated with high morbidity and profound effects on the quality of life of patients and their families. Drug-refractory seizures are a hallmark and treatment is further complicated by its multiple morbidities, which evolve over the patient's lifetime. This review provides a comprehensive overview of the current and future options for the treatment of seizures associated with LGS. Six treatments are specifically indicated as adjunct therapies for the treatment of seizures associated with LGS in the US: lamotrigine, clobazam, rufinamide, topiramate, felbamate and most recently cannabidiol. These therapies have demonstrated reductions in drop seizures in 15%-68% of patients across trials, with responder rates (≥ 50% reduction in drop seizures) of 37%-78%. Valproate is still the preferred first-line treatment, generally in combination with lamotrigine or clobazam. Other treatments frequently used off-label include the broad spectrum anti-epileptic drugs (AED) levetiracetam, zonisamide and perampanel, while recent evidence from observational studies has indicated that a newer AED, the levetiracetam analogue brivaracetam, may be effective and well tolerated in LGS patients. Other treatments in clinical development include fenfluramine in late phase III, perampanel, soticlestat-OV953/TAK-953, carisbamate and ganaxolone. Non-pharmacologic interventions include the ketogenic diet, vagus nerve stimulation and surgical interventions; these are also expanding, with the potential for less invasive techniques for corpus callosotomy that have promise for reducing complications. However, despite these advancements, patients continue to experience a significant burden. Because LGS is not a single entity, tailoring of treatment is needed as opposed to a 'one size fits all' approach. Further research is needed into the underlying aetiologies and pathophysiology of LGS, together with advancements in treatments that encompass the spectrum of seizures associated with this complex syndrome.

General approach to treatment of genetic leukoencephalopathies in children and adults

New Clinical Characteristics and Novel Pathogenic Variants of Patients with Hereditary Leukodystrophies

[Genetic testing in neurological diseases: a practical guide]

The Use Of Targeted Genomic Capture And Massively Parallel Sequencing In Diagnosis Of Chinese Leukoencephalopathies

Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials

Approaches to diagnosis for individuals with a suspected inherited white matter disorder

Neurodegeneation treatment in lysosomal diseases. An update

Developmental and Epileptic Encephalopathies: Need for Bridging the Gaps Between Clinical Syndromes and Underlying Genetic Etiologies

Research Advances in the Clinical Genetics of Leukodystrophy in Children

Etiological spectrum of pediatric onset leukodystrophies and genetic leukoencephalopathies: the five-year experience of a tertiary care centre in southern India

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Current Pharmacological Treatment Approaches to Central Nervous System Leukaemia

Advances in Personalized Diagnosis and Treatment of Treatable Genetic Diseases of Pediatric Neurology in Precision Medicine Period

Genetic Treatment Approaches in Rare Pediatric Diseases

[Leukoencephalopathy in childhood leukemia (author's transl)]

Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae

Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

Genetic Diagnosis in Neonatal Encephalopathy With Hypoxic Brain Damage Using Targeted Gene Panel Sequencing

The Conundrum of Mechanics Versus Genetics in Congenital Hydrocephalus and Its Implications for Fetal Therapy Approaches: A Scoping Review